Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To assess whether overall survival time in subjects receiving cetuximab in combination with cisplatin or carboplatin + 5-FU is prolonged compared to subjects receiving cisplatin or carboplatin + 5-FU only, in the first-line treatment of recurrent and/or metastatic SCCHN.
Inclusion criteria
- Recurrent and/or metastatic Squamous cell carcinoma of the head and neck (SCCHN)